Ra Pharmaceuticals IPO

10/26/2016

IPO

$91,000,000

We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows: approximately $33.0 million to fund clinical development of RA101495 through the completion of a Phase 2 clinical trial in PNH patients; approximately $11.0 million to fund a Phase 2 clinical trial in rMG patients and a Phase 1b clinical trial in LN patients; approximately $18.9 million to advance our pipeline programs in Factor D, oral C5 inhibition and C1s; and the remainder, if any, for working capital and other general corporate purposes.

Acquired or Merged

Biopharmaceutical

87 Cambridge Park Dr.
Cambridge, MA 02140
USA

Ra Pharmaceuticals is developing Cyclomimetics, a new drug class with the diversity and specificity of antibodies, coupled with the many benefits of small molecules. Ra Pharma's peptide-like molecules are highly-stable, synthetic products with chemical structures that offer intrinsic cell permeability.